ID: ALA5280283

Max Phase: Preclinical

Molecular Formula: C20H24F3N3O3

Molecular Weight: 411.42

Associated Items:

Representations

Canonical SMILES:  CC(C)(O)[C@H]1CC[C@H](NC(=O)c2cnc3nc(OCC(F)(F)F)ccc3c2)CC1

Standard InChI:  InChI=1S/C20H24F3N3O3/c1-19(2,28)14-4-6-15(7-5-14)25-18(27)13-9-12-3-8-16(26-17(12)24-10-13)29-11-20(21,22)23/h3,8-10,14-15,28H,4-7,11H2,1-2H3,(H,25,27)/t14-,15-

Standard InChI Key:  LPPRCJPNXIMGPZ-SHTZXODSSA-N

Associated Targets(Human)

Hematopoietic prostaglandin D synthase 658 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Hematopoietic prostaglandin D synthase 77 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 411.42Molecular Weight (Monoisotopic): 411.1770AlogP: 3.63#Rotatable Bonds: 5
Polar Surface Area: 84.34Molecular Species: NEUTRALHBA: 5HBD: 2
#RO5 Violations: 0HBA (Lipinski): 6HBD (Lipinski): 2#RO5 Violations (Lipinski): 0
CX Acidic pKa: 13.95CX Basic pKa: CX LogP: 3.13CX LogD: 3.13
Aromatic Rings: 2Heavy Atoms: 29QED Weighted: 0.79Np Likeness Score: -0.96

References

1. Cadilla R, Deaton DN, Do Y, Elkins PA, Ennulat D, Guss JH, Holt J, Jeune MR, King AG, Klapwijk JC, Kramer HF, Kramer NJ, Laffan SB, Masuria PI, McDougal AV, Mortenson PN, Musetti C, Peckham GE, Pietrak BL, Poole C, Price DJ, Rendina AR, Sati G, Saxty G, Shearer BG, Shewchuk LM, Sneddon HF, Stewart EL, Stuart JD, Thomas DN, Thomson SA, Ward P, Wilson JW, Xu T, Youngman MA..  (2020)  The exploration of aza-quinolines as hematopoietic prostaglandin D synthase (H-PGDS) inhibitors with low brain exposure.,  28  (23): [PMID:33059303] [10.1016/j.bmc.2020.115791]

Source